We are pleased to share with you an exciting development in the field of nuclear medicine. INITIO Medical Group has recently been granted a therapeutic license to administer a new drug to treat prostate cancer.

The drug, which has been approved by Health Canada, targets prostate-specific membrane antigen (PSMA), a protein that is overexpressed in prostate cancer cells. The drug is a radiopharmaceutical that emits radiation directly to the cancer cells, allowing for targeted treatment of the disease.

This is a significant milestone for the field of nuclear medicine and for the treatment of prostate cancer. INITIO Medical Group is one of the first facilities in Canada to be licensed to administer this new therapy, and it is expected to provide an effective and efficient treatment option for patients with prostate cancer.

We encourage all members of the Canadian Association of Nuclear Medicine to stay informed and up-to-date on this exciting development, as it has the potential to significantly impact the way we approach the treatment of prostate cancer.

We would like to extend our congratulations to INITIO Medical Group on this achievement and wish them all the best as they continue to provide innovative and cutting-edge care to their patients.

‍